Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
32 participants
INTERVENTIONAL
2025-11-17
2026-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a randomized, double-blind, placebo-controlled, dose-escalation trial consisting of four ascending dose cohorts. Each cohort will enroll eight participants, including six receiving BT01001 Ophthalmic Solution and 2 receiving Placebo.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers
NCT06978244
Safety and Tolerability of NTX-101 in Korean Healthy Volunteers
NCT05041543
Phase 1 Study for Safety and Tolerability of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects
NCT01748578
A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye
NCT04633213
A Pharmacokinetics (PK) Study in Healthy Adults
NCT06911216
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BT01001 Ophthalmic Solution dose 1 SAD
• BT01001 Ophthalmic Solution 5 mg/ml (0.5%） N = 6 Single Ascending Dose (SAD, Day 1): 2 drops administered once to the right eye. Elution/Washout Phase: 1 day following SAD.
BT01001 5 mg/ml（0.5%）
BT01001 Ophthalmic Solution will be administered as topical instillation into the right eye of each subject according to the assigned dosing schedule.
Placebo dose 1 SAD
• Placebo Ophthalmic Solution (0 mg/mL) N = 2 Single Ascending Dose (SAD, Day 1): 2 drops administered once to the right eye. Elution/Washout Phase: 1 day following SAD.
Placebo
Placebo BT01001 Ophthalmic Solution will be administered as a topical instillation into the right eye of each subject following the same dosing schedule as the active treatment.
BT01001 Ophthalmic Solution dose 1 MAD
• BT01001 Ophthalmic Solution 5 mg/ml (0.5%） N = 6 Multiple Ascending Dose (MAD, Days 3-9): 2 drops administered twice daily (BID) from Days 3 to 8; on Day 9, 2 drops administered once in the morning only. Dose Administration: 2 drops with three minutes interval per dosing time.
BT01001 5 mg/ml（0.5%）
BT01001 Ophthalmic Solution will be administered as topical instillation into the right eye of each subject according to the assigned dosing schedule.
Placebo dose 1 MAD
• Placebo Ophthalmic Solution (0 mg/mL) N = 2 Multiple Ascending Dose (MAD, Days 3-9): 2 drops administered twice daily (BID) from Days 3 to 8; on Day 9, 2 drops administered once in the morning only. Dose Administration: 2 drops with three minutes interval per dosing time.
BT01001 15 mg/ml（1.5%）
BT01001 Ophthalmic Solution will be administered as topical instillation into the right eye of each subject according to the assigned dosing schedule.
BT01001 Ophthalmic Solution dose 2 SAD
• BT01001 Ophthalmic Solution 10 mg/ml (1.0%） N = 6 Single Ascending Dose (SAD, Day 1): 2 drops administered once to the right eye.
Elution/Washout Phase: 1 day following SAD.
BT01001 10 mg/ml（1.0%）
BT01001 Ophthalmic Solution will be administered as topical instillation into the right eye of each subject according to the assigned dosing schedule.
Placebo dose 2 SAD
• Placebo Ophthalmic Solution (0 mg/mL) N = 2 Single Ascending Dose (SAD, Day 1): 2 drops administered once to the right eye. Elution/Washout Phase: 1 day following SAD.
Placebo
Placebo BT01001 Ophthalmic Solution will be administered as a topical instillation into the right eye of each subject following the same dosing schedule as the active treatment.
BT01001 Ophthalmic Solution dose 2 MAD
• BT01001 Ophthalmic Solution 10 mg/ml (1.0%） N = 6 Multiple Ascending Dose (MAD, Days 3-9): 2 drops administered twice daily (BID) from Days 3 to 8; on Day 9, 2 drops administered once in the morning only. Dose Administration: 2 drops with three minutes interval per dosing time.
BT01001 10 mg/ml（1.0%）
BT01001 Ophthalmic Solution will be administered as topical instillation into the right eye of each subject according to the assigned dosing schedule.
Placebo dose 2 MAD
• Placebo Ophthalmic Solution (0 mg/mL) N = 2 Multiple Ascending Dose (MAD, Days 3-9): 2 drops administered twice daily (BID) from Days 3 to 8; on Day 9, 2 drops administered once in the morning only. Dose Administration: 2 drops with three minutes interval per dosing time.
Placebo
Placebo BT01001 Ophthalmic Solution will be administered as a topical instillation into the right eye of each subject following the same dosing schedule as the active treatment.
BT01001 Ophthalmic Solution dose 3 SAD
• BT01001 Ophthalmic Solution 15 mg/ml (1.5%） N = 6 Single Ascending Dose (SAD, Day 1): 2 drops administered once to the right eye.
Elution/Washout Phase: 1 day following SAD.
BT01001 15 mg/ml（1.5%）
BT01001 Ophthalmic Solution will be administered as topical instillation into the right eye of each subject according to the assigned dosing schedule.
Placebo dose 3 SAD
• Placebo Ophthalmic Solution (0 mg/mL) N = 2 Single Ascending Dose (SAD, Day 1): 2 drops administered once to the right eye. Elution/Washout Phase: 1 day following SAD.
Placebo
Placebo BT01001 Ophthalmic Solution will be administered as a topical instillation into the right eye of each subject following the same dosing schedule as the active treatment.
BT01001 Ophthalmic Solution dose 3 MAD
• BT01001 Ophthalmic Solution 15 mg/ml (1.5%） N = 6 Multiple Ascending Dose (MAD, Days 3-9): 2 drops administered twice daily (BID) from Days 3 to 8; on Day 9, 2 drops administered once in the morning only. Dose Administration: 2 drops with three minutes interval per dosing time.
BT01001 15 mg/ml（1.5%）
BT01001 Ophthalmic Solution will be administered as topical instillation into the right eye of each subject according to the assigned dosing schedule.
Placebo dose 3 MAD
• Placebo Ophthalmic Solution (0 mg/mL) N = 2 Multiple Ascending Dose (MAD, Days 3-9): 2 drops administered twice daily (BID) from Days 3 to 8; on Day 9, 2 drops administered once in the morning only. Dose Administration: 2 drops with three minutes interval per dosing time.
Placebo
Placebo BT01001 Ophthalmic Solution will be administered as a topical instillation into the right eye of each subject following the same dosing schedule as the active treatment.
BT01001 Ophthalmic Solution dose 4 MAD
• BT01001 Ophthalmic Solution 15 mg/ml (1.5%） N = 6 Multiple Ascending Dose (MAD, Days 1-7): 2 drops administered three times daily (TID) from Days 1 to 6; on Day 7, 2 drops administered once in the morning only to the right eye.
Dose Administration: 2 drops with three minutes interval per dosing time.
BT01001 15 mg/ml（1.5%）
BT01001 Ophthalmic Solution will be administered as topical instillation into the right eye of each subject according to the assigned dosing schedule.
Placebo dose 4 MAD
• Placebo Ophthalmic Solution (0 mg/mL) N = 2 Multiple Ascending Dose (MAD, Days 1-7): 2 drops administered three times daily (TID) from Days 1 to 6; on Day 7, 2 drops administered once in the morning only to the right eye.
Dose Administration: 2 drops with three minutes interval per dosing time.
Placebo
Placebo BT01001 Ophthalmic Solution will be administered as a topical instillation into the right eye of each subject following the same dosing schedule as the active treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BT01001 5 mg/ml（0.5%）
BT01001 Ophthalmic Solution will be administered as topical instillation into the right eye of each subject according to the assigned dosing schedule.
BT01001 10 mg/ml（1.0%）
BT01001 Ophthalmic Solution will be administered as topical instillation into the right eye of each subject according to the assigned dosing schedule.
BT01001 15 mg/ml（1.5%）
BT01001 Ophthalmic Solution will be administered as topical instillation into the right eye of each subject according to the assigned dosing schedule.
Placebo
Placebo BT01001 Ophthalmic Solution will be administered as a topical instillation into the right eye of each subject following the same dosing schedule as the active treatment.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Healthy male or female participant, 18 to 50 years of age at the time of screening, who are in good health based on medical history, physical examinations, vital signs, electrocardiogram (ECG), and clinical laboratory evaluations.
2. Body Mass Index (BMI) between 18.0 and 27.0 kg/m² (inclusive).
3. Negative alcohol breath test and negative urine drug screen at screening.
4. Willing and able to comply with all study procedure and capable of good communication with study personnel.
5. Participants of childbearing potential must agree to abstain from sexual intercourse or use an effective method of contraception from screening until 90 days after the final study drug administration; Female participants of childbearing potential must have a negative urine pregnancy test at screening.
6. Able to understand the study procedure and voluntarily sign the written informed consent form.
7. Corrected vision acuity ≥ 0.8 in both eyes.
8. Intraocular pressure (IOP) \< 21 mmHg in each eye, with and inter-eye difference \< 4 mmHg.
9. Slit-lamp and ophthalmoscopic examinations that are normal or show abnormalities considered not clinically significant by the investigator.
Exclusion Criteria
1. Known or suspected hypersensitivity to any component of the investigational product, or a history of multiple allergies two or more allergens).
2. History or presence of any clinically significant diseases or abnormality, including but not limited to cardiovascular, cerebrovascular, respiratory, endocrine, metabolic, renal, hepatic, gastrointestinal, dermatologic, oncologic, hematologic, immunologic, infectious, neurologic or psychiatric conditions, or any acute or chronic condition that may interfere with study assessments.
3. Participation in any investigational drug or medical device trial within 90 days prior to study drug administration.
4. Use of prescription or over-the-counter medications within 14 days prior to dosing, or unwillingness to discontinue such medications during the study.
5. Receipt of systemic corticosteroid therapy within 6 months prior to dosing.
6. History of alcohol abuse or substance abuse within 2 years prior to dosing.
7. Regular smoking of ≥ 5 cigarettes per day (or equivalent tobacco use) within 12 weeks prior to screening, or inability/unwillingness to abstain during the study.
8. Average alcohol consumption \>14 units per week within 12 weeks prior to screening (1 unit approximately equivalent to 360 mL beer, 150 mL wine, or 45 mL of 40% spirits).
9. History or evidence of intravenous illicit drug use; positive test for HIV, HCV, HBsAg, anti-HCV, anti-HIV, or Treponema pallidum antibody at screening.
10. Blood donation or receipt of blood products within 30 days prior to dosing.
11. History of bleeding disorders or coagulation abnormalities.
12. Clinically significant abnormalities on physical examination, vital signs, 12-lead ECG, or laboratory results at screening.
Abnormal findings that normalize on repeat testing may be accepted if assessed not clinically significant by the investigator.
13. Current or past use of bariatric medications or history of bariatric surgery (e.g., gastric bypass).
14. Impaired mental status or other factors that may compromise adherence to study requirements.
15. Any conditions that, in the investigator's judgment, may interfere with study assessments or pose the participant to unacceptable risks.
16. History of ocular surgery, ocular trauma, or chronic eye disease.
17. Current use of contact lenses or use within 2 weeks prior to first dosing.
18. Ocular abnormalities or symptoms considered clinically significant by the investigator.
19. Use of intraocular injectable or implantable therapies, or topical ophthalmic medications, within 2 months prior to dosing, or expected need during the study.
20. History or evidence of ocular e infection, inflammation, blepharitis, or conjunctivitis within 2 months; history of herpes simplex keratitis.
21. Clinically significant findings on ophthalmic evaluations (slit lamp, BCVA, IOP, OCT/OCTA, or fundus examination) that, in the investigator's judgment, may interfere with ocular safety evaluations.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beyang Therapeutics Co., Ltd.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai General Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BT01001-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.